News

From May 3rd to 5th, Kaitlyn Begins will be attending the Protein Engineering Summit (PEGS) at the Seaport World Trade Center in Boston, Massachusetts. Kaitlyn will be going to expand Green Mountain Antibodies’ knowledge of engineering antibodies for expression in mammalian cells. She will also be focusing on talks relating to new biologics and therapeutics for infectious disease. If you would like to schedule a time to meet with Kaitlyn at the PEGS, you can reach her at Kaitlyn@greenmoab.com.

{ 0 comments }

 

Green Mountain Antibodies has signed an agreement with the International Livestock Research Institute (ILRI) of Nairobi, Kenya to produce and distribute monoclonal antibodies that detect infectious disease markers in cattle. This agreement is a result of a collaboration between Green Mountain Antibodies, ILRI, Dr. John Barlow of the University of Vermont, and Dr. Bill Golde, currently of the Moredun Research Institute, Edinburgh, Scotland. This agreement allows Green Mountain Antibodies access to existing antibodies and will lead to greater world-wide availability of high-quality, validated antibodies for animal health diagnostics.

Monoclonal antibodies are created by fusing an antibody-producing white blood cell with a cancer cell, resulting in a hybrid cell that produces identical antibodies and is immortal when grown in the laboratory. Monoclonal antibodies are one of the foundations of biotechnology and are used as therapeutics for human health and diagnostics for human and animal diseases.

With close to 1.5 billion cows on the planet, and in Vermont almost 1 cow for every 2 humans, livestock production for food competes for natural resources and is a significant contributor to global warming. With current regulatory efforts to decrease routine use of antibiotics in food, vaccines become increasingly important to prevent disease. Monoclonal antibodies to blood markers can indicate if a vaccine is protecting an individual from a bacterial, viral, or parasitic disease following vaccination. Since many infectious diseases in livestock also infect humans, improvements in livestock vaccines will positively affect human health.

Dr. Bill Church of Green Mountain Antibodies believes “producing smaller numbers of healthier and higher value animals will relieve some of the contribution of food production on climate change, and at the same time, in the developing world, let small farmers improve their standard of living by having healthier animals. We are excited that ILRI recognizes our strengths in antibody manufacturing and we share their vision of producing healthy animals for a healthier world.”

 

For more information, contact Anna Hill at (802) 865-6230 or by email at AHill@greenmoab.com.

{ 0 comments }

New Additions to Our Anti-Factor VIII Product Line

April 10, 2017
Thumbnail image for New Additions to Our Anti-Factor VIII Product Line

Green Mountain Antibodies is excited to announce the addition of four new antibodies to our already extensive anti-factor VIII antibody collection. Information on GMA-8027, GMA-8040, GMA-8041, and GMA-8045, as well as the full collection, can be viewed here:  http://greenmoab.com/product-category/factor-viii/.  Are there antibodies we’re missing that you need for your research project?  Let us know at […]

Read the full article →

Scientists at GMA Collaborate on Bovine Cytokine Project

October 11, 2016

Scientists at Green Mountain Antibodies have recently collaborated with the USDA and the University of Vermont to produce novel murine monoclonal antibodies to bovine cytokines IL-13 and IL-17A. IL-13 induces B-cell activation and proliferation and possesses anti-inflammatory properties, while IL-17A is primarily responsible for the proinflammatory mechanisms of chronic inflammatory states. Monoclonal antibodies were generated […]

Read the full article →

Congrats to Long-Time GMA Collaborators

August 8, 2016
Thumbnail image for Congrats to Long-Time GMA Collaborators

The recent Nature Medicine publication, ‘A rapid pro-hemostatic approach to overcome direct oral anticoagulants,’ addresses the growing need for effective and clinically viable drugs that control bleeding after anticoagulant administration. Researchers at The Children’s Hospital of Philadelphia have developed a potent variant, designated Factor Xa(I16L), that significantly reduces bleeding and restores normal hemostatic processes. Congratulations […]

Read the full article →

GMA Antibodies Featured in Blood Publication

August 4, 2016
Thumbnail image for GMA Antibodies Featured in Blood Publication

The recent Blood article, ‘Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice,’ features three GMA antibodies. Antibodies to human Factor IX (GMA-101), human Factor X (GMA-540), and human Factor VII (GMA-213) were used in combination with an anti-collagen antibody to demonstrate localization of coagulation factors in human tissues. The study finds that not […]

Read the full article →

New Additions to Our Anti-Factor IX Product Line

July 26, 2016
Thumbnail image for New Additions to Our Anti-Factor IX Product Line

Green Mountain Antibodies is excited to announce the expansion of our anti-Factor IX product line of monoclonal antibodies. Thank you to all of our collaborators who have helped us in determining specificities of interest and testing products in the developmental stage; our line now contains an additional 6 antibodies with more detailed information on the […]

Read the full article →

Gordon Research Conference on Hemostasis

July 20, 2016
Thumbnail image for Gordon Research Conference on Hemostasis

From July 24th to 29th, Amy Griffiths and Dr. Bill Church will be attending the Gordon Research Conference on Hemostasis at the Stoweflake Conference Center, located in Stowe, VT. They will be participating in discussions on a variety of conference topics, including the relationship between Von Willebrand Factor and Factor VIII and the role of […]

Read the full article →

New Antibodies to S. aureus virulence factors to be discussed at American Society of Microbiology meeting in Boston, June 2016.

May 3, 2016

In collaboration with Drs. Paul Bock and Ashok Maddur of Vanderbilt University, and Dr. Pete Panizzi of Auburn University, Green Mountain Antibodies scientists have prepared monoclonal antibodies to the major known procoagulant virulence factors from S. aureus: coagulase and von Willebrand factor binding protein.  The rationale behind preparing these antibodies is the hypothesis that blocking […]

Read the full article →

Kaitlyn Begins promoted to Research Project Manager

May 3, 2016

  Kaitlyn Begins was promoted to Research Project Manager effective May 1, 2016.  Kaitlyn joined Green Mountain Antibodies as an intern following graduation from St. Michael’s College and became a full time lab technician in the fall of 2011.  In addition to her responsibilities overseeing our variable region sequencing and human antibody construction and expression […]

Read the full article →